What Supreme Court’s Myriad decision means for biopharma companies
On 13 June 2013, the US Supreme Court ruled that certain patent claims owned by Myriad Genetics, the US biotech company that holds the patents covering a test for breast-cancer-related genes (BRCA1 and BRCA2), are invalid as products of nature.
The court held that a naturally occurring DNA segment is ‘a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring’.
Key to the decision was the finding that isolating DNA from the human genome does not change the chemical structure, nor does it alter the genetic information encoded in the BRCA1 and BRCA2 genes. In other words, the sequence and coding information is inherent in that gene, isolated or not…
If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
The Financial Report — Fed study questions new money market rules; Singapore updates audit committee guidebook; and more
DLA Piper has released the latest version (Volume 3, No.16) of The Financial Report, featuring news and analysis from across the financial sector.
The National Bank of Ukraine has toughened requirements for the mandatory sale of international currency proceeds that was temporarily introduced in November 2012.
Analysis from The Lawyer
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.
A new breed of lawyer is smoothing the path for companies entering emerging or unstable jurisdictions